ProPath Announces Preferred Provider Partnership with Promega’s Microsatellite Instability (MSI) for Precision Medicine

DALLAS, TX, September 6, 2018 – ProPath is pleased to announce that it has become a Preferred Provider of Promega’s Microsatellite Instability (MSI) Analysis System for use in clinical trials. ProPath has over seven years of experience with Promega’s MSI technology, the gold standard in determining MSI status, and has analyzed thousands of specimens. In addition, the two companies will conduct collaborative research studies on applications and advantages of new MSI markers developed by Promega.

MSI testing detects DNA mismatch repair (MMR) deficiency in tumor tissue. It was originally developed as an aid to help identify if further testing was needed to determine Lynch Syndrome, an inherited genetic disorder that predisposes individuals to developing cancer. More recently, the MMR deficiency-MSI complex has been recognized as a powerful biomarker for predicting response to a group of cancer therapeutics called checkpoint inhibitors. These new drugs have demonstrated significant potential to greatly impact cancer care.

“This announcement further underscores the commitment Promega and ProPath are making to advancing microsatellite instability as an important marker in evaluating tumor status,” noted Dr. Heather Tomlinson, Director of Clinical Diagnostics. The MSI Assay is reimbursable, has a fast turnaround time and most importantly there is a large body of evidence supporting use of the Promega’s MSI assay as part of a lab developed test. Promega announced their intent to seek FDA approval with their MSI assay last year.

“We are excited to partner with a great company like Promega in providing MSI testing.” said Dr. Cory Roberts, President and CEO of ProPath. “Promega’s market-leading expertise complements our experience in delivering the most accurate, timely results.”

About ProPath

ProPath is a physician-owned pathology practice with nearly 50 board-certified, sub-specialty trained pathologists, providing diagnostic expertise and conducting research for all cancer types. In addition to the Promega MSI test, ProPath offers a large menu of diagnostic, prognostic, and predictive assays for optimizing the personalized selection of therapeutics.

For Press inquiries contact:

Douglas Kale

Marketing Manager – [email protected]